These gains stem from the sector’s ability to maintain growth momentum, supported by new product launches, stable generics ...
Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...
The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
Despite its government spending more than any other on health care both per capita and as a percentage of GDP, spending over $4.5 trillion in 2022, the United States has the lowest life expectancy at ...
On FDA drug approvals and the American diet.
With a market capitalization of just $1.9 billion, Recursion still provides a potentially good entry point for investors, but that's only if there are good reasons to think that its strategy will pan ...
The Nifty Pharma has gained around 37% year to date. The growth continues to be led by the US sales and well supported by ...
In a bid to break down barriers facing both pharmas and payers in the life sciences industry, AscellaHealth has begun ...
Citi analyst David Lebowitz has maintained their neutral stance on BMRN stock, giving a Hold rating on September 17. David Lebowitz has given ...
Pharma Industry Awards 2024 organiser BusinessRiver, asks senior Cognizant managers for their predictions for the year ahead.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback